Source and scope
This summary is bounded to the recommendations, population and decisions covered by STI-associated syndromes guide: Pelvic inflammatory disease. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:PHAC PID
Source-attributed clinical priorities
- Maintain a low threshold for empiric treatment when pelvic pain and examination support PID and no better diagnosis is evident.
- Test for gonorrhea, chlamydia, pregnancy and other relevant infections without delaying treatment.
- Escalate pregnancy, severe illness, tubo-ovarian abscess, inability to tolerate oral therapy or an uncertain surgical diagnosis.
- Treat empirically when the clinical threshold is met because delay can increase reproductive harm.
sources for this section:PHAC PID
Practical assessment and management workflow
1
Assess pregnancy, pelvic pain, bleeding, discharge, fever, STI exposure and severity.
2
Perform abdominal and pelvic examination with consent and collect STI, pregnancy and other indicated tests.
3
Start broad empiric treatment and arrange partner management without waiting for every result.
4
Review within a short interval for improvement and counsel about abstinence until treatment and partner care are complete.
sources for this section:PHAC PID
Safety, red flags and urgent escalation
- Pregnancy, severe illness, tubo-ovarian abscess, vomiting or surgical diagnostic uncertainty may require admission.
- Exclude ectopic pregnancy and appendicitis in acute pelvic pain.
- Failure to improve promptly needs urgent reassessment and possible imaging or specialist care.
sources for this section:PHAC PID
Confirm the local pathway before acting
The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:PHAC PID
Source and implementation boundary
Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:PHAC PID
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- Public Health Agency of CanadaSTI-associated syndromes guide: Pelvic inflammatory diseaseaccessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the Canada question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.